Record Revenue and Margin Expansion
Revenue grew 7% to $36 million with gross margins expanding by 574 basis points to 55.2%, resulting in a 32% year-over-year increase in adjusted EBITDA to $8 million.
Significant Increase in Net Income and Cash Flow
Net income increased by 262%, and cash flows from operations more than doubled for the quarter and year-to-date.
Operational Efficiency and Shareholder Returns
Operating cash flow increased by $6 million over the prior year with a significant reduction in capital expenditures by $4.2 million. Approximately $3.5 million was returned to shareholders through stock repurchases during the quarter.
Positive Outlook for Oncology and Device Solutions
Oncology revenue increased by 4.5% and investments in Device Solutions are paying off, contributing to increased revenue and maintaining high operating cash margins.